Pharma and biotech segment continued to dominate dealmaking, accounting for 26 per cent of overall deals, according to a Grant Thornton Bharat’s Pharma and Healthcare Dealtracker.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment